Zylofuramine

Zylofuramine is one of a family of tetrahydrofurfurylamine stimulants explored in the early 1960s as part of a broad search for psychomotor stimulants that might separate wakefulness and anorectic activity from the liabilities of amphetamine. The foundational study described its pharmacology across several species, examining effects on behavior, blood pressure, body temperature, appetite and central nervous system activity and comparing it with reference stimulants such as dextroamphetamine and chlorpromazine ^[1].

Because interest in the series did not lead to a lasting approved product, modern data on zylofuramine are essentially absent. There are no contemporary clinical trials, pharmacokinetic studies in humans, or safety surveillance to draw on, so any account of its effects rests on decades-old animal pharmacology. It should be regarded as a historical stimulant of uncertain human profile, now sold only as an unapproved research chemical.

Zylofuramine has no established modern safety data and is an unapproved research chemical. As a central stimulant and appetite suppressant, it would be expected to carry the usual stimulant risks such as insomnia, reduced appetite, increased heart rate and blood pressure, and anxiety, and the original animal work examined cardiovascular and temperature effects. Human dosing and long-term safety are unknown. It is sold for laboratory research only and is not intended for human consumption.

Zylofuramine was developed under the Sterling-Winthrop code WIN 25873 and reported in 1963 as part of a series titled alpha-benzyltetrahydrofurfurylamines, described as a new class of psychomotor stimulants. It reflects the mid-century pharmaceutical effort to find non-amphetamine stimulants and anorectics, but it did not achieve lasting therapeutic adoption.

Zylofuramine is an obscure and largely forgotten stimulant with almost no modern following or literature. It is occasionally offered as a research chemical curiosity; there is no meaningful body of user experience or clinical evidence, and it is best regarded as a historical footnote in stimulant pharmacology.